公开(公告)号：WO2022069419A1

公开(公告)日：2022-04-07

申请号：PCT/EP2021/076545

申请日：2021-09-27

Applicant: CRM THERAPEUTICS B.V.

Inventor： BOER, DE, Albertus Gerrit ,  MARING, Markwin Hendrik

IPC: A61K47/62 ,  A61K47/69 ,  A61K49/18 ,  A61K49/00 ,  A61K51/12 ,  A61K31/573 ,  A61K31/704 ,  A61K38/16 ,  A61K48/00 ,  A61P25/00 ,  A61P31/18 ,  A61P35/00 ,  A61K38/162 ,  A61K47/6911 ,  A61K48/005 ,  A61K49/0056 ,  A61K49/006 ,  A61K49/0084 ,  A61K49/1812 ,  A61K51/1234

Abstract: The present invention is in the field of Intelligent Drug Delivery. Targeted medicines have been developed thereto, using a Targeted Mediated Drug Delivery-technology. This technology leads drugs selectively and specifically into diseased cells/organs, in contrast to "dumping" drugs into the body. This technology is found to substantially increase the efficacy of disease treatment and reduce side-effects while much smaller amounts of drug(s) are required. In addition, a novel innovative approach is used that can be applied in the treatment of e.g. cancers, auto-immune diseases, viral diseases, transplantation, and diseases associated with inflammation.

公开(公告)号：WO2021054927A2

公开(公告)日：2021-03-25

申请号：PCT/US2019/000039

申请日：2019-08-12

Applicant: SOUTH DAKOTA BOARD OF REGENTS

Inventor： GUAN, Xiangming ,  NAJMI, Asidim ,  WANG, Shenggang ,  HUANG, Yue ,  SEEFELDT, Teresa ,  ALQAHTANI, Yahya

IPC: A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K47/28 ,  A61K38/00 ,  A61K47/20 ,  A61K47/6907 ,  A61K47/6911 ,  A61K49/0032 ,  A61K49/0082 ,  A61K49/0084 ,  A61K9/0019 ,  A61K9/1075 ,  C07K5/0215

Abstract: The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.